Article
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
Annals of clinical microbiology and antimicrobials - 14 Apr 2016
Yang Song, Xing Huichun, Wang Qi, Wang Xiaomei, Liu Shunai, Cheng Jun
Abstract excerpt
BACKGROUND: Entecavir-resistance mutations are commonly induced by entecavir treatment in chronic hepatitis B patients. However, entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations induced by sequential or combination treatment with lamivudine and adefovir dipivoxil have never been reported. RESULTS: We retrospectively reviewed 1200 patients who had been tested for anti-HBV drug resistance at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.